Larimar Therapeutics (LRMR) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 22.4% versus a loss of 44.0%. Over five years, LRMR leads with a -77.7% price change compared with -90.6% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($288.7 million vs $280.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | RCKT |
|---|---|---|
| Share price | $2.70 | $2.63 |
| Market cap | $280.48M | $288.71M |
| 1-day change | -1.82% | +3.75% |
| YTD return | -29.13% | -25.07% |
| 1-year return | -43.98% | -22.42% |
| 5-year return | -77.72% | -90.58% |
| EPS (TTM) | $-1.99 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $5.45 |
| 52-week low | $2.61 | $2.42 |
| Distance from 52-week high | -57.94% | -51.74% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +433.33% | +223.19% |
| Average volume | 1.27M | 1.66M |
| Shares outstanding | 103.88M | 109.77M |
| Employees | 71 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed LRMR by 21.6 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
LRMR vs RCKT FAQ
Which is bigger, Larimar Therapeutics or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $288.71M compared with $280.48M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, LRMR or RCKT?
RCKT returned -22.42% over the past 12 months, compared with -43.98% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.